Most coagulation results still come back from a central lab. That delay shapes what a clinician can do in the room. Heagital is developing a point-of-care coagulation device and companion app for NHS settings, so the result arrives during the consultation rather than after it.
In development. Not yet UKCA marked. Not available for sale.
A benchtop-free coagulation analyser designed for use at the point of care. The target assay panel is PT, INR and APTT from a capillary sample. Intended settings are anticoagulation clinics, community care and acute assessment. Currently in development.
DeviceResults from the device feed a companion application that records readings over time, flags values outside the therapeutic range, and gives the clinician a trend rather than a single number. Designed to fit existing anticoagulation workflows.
SoftwareWe are building toward UKCA conformity under the UK IVDR framework, with clinical validation and pilot design planned alongside it. Deployment priorities are set by an internal model that ranks all 42 NHS Integrated Care Boards on clinical risk, adoption readiness and procurement friction.
RegulatoryFour founders. Biomedical engineering, decision science, systems architecture and finance.
Biomedical engineer. Postgraduate degree from King's College London. Leads company direction, product strategy and the clinical development roadmap.
LinkedInDBA in business intelligence and decision quality. Built the Market Decision Engine that ranks the 42 NHS Integrated Care Boards for deployment priority. Owns market modelling, decision architecture and UK market entry strategy.
LinkedInLeads the technical architecture of the device and the engineering pathway from prototype to clinical-grade build.
Owns financial strategy, fundraising and commercial planning, including the investment case for NHS market entry.
LinkedInHeagital is pre-revenue and currently fundraising. We are looking for investors with MedTech experience, NHS clinical teams willing to shape the pilot design, and research partners for validation work.
Investment, clinical partnership, or validation work. Email us and we will come back to you.